Your browser doesn't support javascript.
loading
Accurate de novo design of hyperstable constrained peptides.
Bhardwaj, Gaurav; Mulligan, Vikram Khipple; Bahl, Christopher D; Gilmore, Jason M; Harvey, Peta J; Cheneval, Olivier; Buchko, Garry W; Pulavarti, Surya V S R K; Kaas, Quentin; Eletsky, Alexander; Huang, Po-Ssu; Johnsen, William A; Greisen, Per Jr; Rocklin, Gabriel J; Song, Yifan; Linsky, Thomas W; Watkins, Andrew; Rettie, Stephen A; Xu, Xianzhong; Carter, Lauren P; Bonneau, Richard; Olson, James M; Coutsias, Evangelos; Correnti, Colin E; Szyperski, Thomas; Craik, David J; Baker, David.
Afiliação
  • Bhardwaj G; Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
  • Mulligan VK; Institute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
  • Bahl CD; Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
  • Gilmore JM; Institute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
  • Harvey PJ; Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
  • Cheneval O; Institute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
  • Buchko GW; Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
  • Pulavarti SV; Institute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
  • Kaas Q; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
  • Eletsky A; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
  • Huang PS; Seattle Structural Genomics Center for Infectious Diseases, Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, Washington 99352, USA.
  • Johnsen WA; Department of Chemistry, State University of New York at Buffalo, Buffalo, New York 14260, USA.
  • Greisen PJ; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
  • Rocklin GJ; Department of Chemistry, State University of New York at Buffalo, Buffalo, New York 14260, USA.
  • Song Y; Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
  • Linsky TW; Institute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
  • Watkins A; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
  • Rettie SA; Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
  • Xu X; Institute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
  • Carter LP; Global Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark.
  • Bonneau R; Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
  • Olson JM; Institute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
  • Coutsias E; Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
  • Correnti CE; Institute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
  • Szyperski T; Cyrus Biotechnology, Seattle, Washington 98109, USA.
  • Craik DJ; Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
  • Baker D; Institute for Protein Design, University of Washington, Seattle, Washington 98195, USA.
Nature ; 538(7625): 329-335, 2016 Oct 20.
Article em En | MEDLINE | ID: mdl-27626386
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks generally have shapes that have evolved to fit precisely into binding pockets on their targets. Such peptides can have excellent pharmaceutical properties, combining the stability and tissue penetration of small-molecule drugs with the specificity of much larger protein therapeutics. The ability to design constrained peptides with precisely specified tertiary structures would enable the design of shape-complementary inhibitors of arbitrary targets. Here we describe the development of computational methods for accurate de novo design of conformationally restricted peptides, and the use of these methods to design 18-47 residue, disulfide-crosslinked peptides, a subset of which are heterochiral and/or N-C backbone-cyclized. Both genetically encodable and non-canonical peptides are exceptionally stable to thermal and chemical denaturation, and 12 experimentally determined X-ray and NMR structures are nearly identical to the computational design models. The computational design methods and stable scaffolds presented here provide the basis for development of a new generation of peptide-based drugs.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Desenho de Fármacos / Desenho Assistido por Computador / Estabilidade Proteica Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Desenho de Fármacos / Desenho Assistido por Computador / Estabilidade Proteica Idioma: En Ano de publicação: 2016 Tipo de documento: Article